clinical trial · NCT05219500
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Metastatic Castration Resistant Prostate CancerFPI-2265
brief summary
The treatment regimen will consist of 4 doses of FPI-2265
started
Dec 16, 2021
primary completion
May 30, 2025
completion
Jul 31, 2026
last updated
Apr 3, 2026
detailed description
The treatment regimen will consist of 4 doses of FPI-2265, administered at 8 ± 1 week intervals, with an initial activity of 100 kilobecquerel (kBq)/kg (±10%).
Additional doses will be administered at 100 kBq/kg (±10%) with the following exceptions:
* Participants who experience dose-modifying events. * Participants with a confirmed decline in PSA\>=50%.
official title
PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol